Galectin Therapeutics (GALT) News Today $2.82 +0.06 (+2.18%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Galectin Therapeutics (NASDAQ:GALT) Raised to Hold at StockNews.comNovember 20 at 3:20 AM | americanbankingnews.comGalectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by StockNews.comStockNews.com upgraded Galectin Therapeutics from a "sell" rating to a "hold" rating in a research note on Wednesday.November 20 at 3:17 AM | marketbeat.comGalectin Therapeutics presents three abstracts at AASLD 2024 Liver MeetingNovember 18 at 7:42 PM | markets.businessinsider.comGalectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver MeetingNovember 18 at 8:00 AM | globenewswire.comHC Wainwright Has Bearish Estimate for GALT FY2027 EarningsGalectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Stock analysts at HC Wainwright dropped their FY2027 earnings estimates for shares of Galectin Therapeutics in a research note issued on Friday, November 15th. HC Wainwright analyst E. Arce now expects that the company will post earnings ofNovember 18 at 4:04 AM | marketbeat.comGalectin Therapeutics Inc. (NASDAQ: GALT) Shares Recent Updates in Latest 8-K FilingNovember 16, 2024 | americanbankingnews.comOptimistic Buy Rating for Galectin Therapeutics: Strategic Trial Design and Financial Stability Boost ProspectsNovember 15, 2024 | markets.businessinsider.comGalectin Therapeutics Reports Increased Q3 LossesNovember 15, 2024 | markets.businessinsider.comGalectin Therapeutics (NASDAQ:GALT) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $11.00 price target on shares of Galectin Therapeutics in a research report on Friday.November 15, 2024 | marketbeat.comGalectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business UpdateNovember 14, 2024 | globenewswire.comGalectin Therapeutics (NASDAQ:GALT) Lowered to Sell Rating by StockNews.comNovember 14, 2024 | americanbankingnews.comInsider Buying: Galectin Therapeutics Inc. (NASDAQ:GALT) Director Purchases 5,000 Shares of StockOctober 17, 2024 | insidertrades.comGalectin Therapeutics Inc. (NASDAQ:GALT) Director Purchases $13,500.00 in StockGalectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) Director Kevin D. Freeman bought 5,000 shares of the firm's stock in a transaction that occurred on Wednesday, October 16th. The shares were acquired at an average price of $2.70 per share, with a total value of $13,500.00. Following the completion of the transaction, the director now directly owns 33,469 shares of the company's stock, valued at $90,366.30. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.October 16, 2024 | marketbeat.comGalectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver MeetingOctober 15, 2024 | globenewswire.comGalectin Therapeutics (NASDAQ:GALT) Upgraded to Hold at StockNews.comStockNews.com upgraded shares of Galectin Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday.October 15, 2024 | marketbeat.comGalectin Therapeutics (NASDAQ:GALT) Rating Increased to Hold at StockNews.comStockNews.com raised shares of Galectin Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday.October 6, 2024 | marketbeat.comGalectin Therapeutics (NASDAQ:GALT) Downgraded by StockNews.comStockNews.com downgraded Galectin Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday.September 28, 2024 | marketbeat.comGalectin Therapeutics (NASDAQ:GALT) Upgraded at StockNews.comStockNews.com raised Galectin Therapeutics from a "sell" rating to a "hold" rating in a report on Friday.September 20, 2024 | marketbeat.comCommonwealth Equity Services LLC Buys 367,610 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT)Commonwealth Equity Services LLC increased its stake in Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) by 317.6% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 483,351 shares of the company's stock after buying an adSeptember 17, 2024 | marketbeat.comGalectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | globenewswire.comGalectin Therapeutics Inc. (NASDAQ:GALT) Sees Significant Growth in Short InterestGalectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) was the target of a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 5,010,000 shares, a growth of 6.4% from the July 31st total of 4,710,000 shares. Currently, 11.6% of the shares of the company are sold short. Based on an average daily trading volume, of 165,400 shares, the days-to-cover ratio is currently 30.3 days.September 2, 2024 | marketbeat.comStock Traders Purchase Large Volume of Put Options on Galectin Therapeutics (NASDAQ:GALT)Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Traders purchased 2,501 put options on the company. This is an increase of approximately 1,282% compared to the average daily volume of 181 put options.August 29, 2024 | marketbeat.comBuy Rating Affirmed for Galectin Therapeutics Ahead of Phase 2b Interim Analysis and with Strong Cash PositionAugust 21, 2024 | markets.businessinsider.comHC Wainwright Comments on Galectin Therapeutics Inc.'s Q1 2025 Earnings (NASDAQ:GALT)Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Galectin Therapeutics in a note issued to investors on Friday, August 16th. HC Wainwright analyst E. Arce forecasts that the company willAugust 19, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Galectin Therapeutics (NASDAQ:GALT)HC Wainwright reaffirmed a "buy" rating and issued a $11.00 target price on shares of Galectin Therapeutics in a report on Friday.August 16, 2024 | marketbeat.comGalectin Therapeutics (NASDAQ:GALT) Announces Earnings ResultsGalectin Therapeutics (NASDAQ:GALT - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.04).August 15, 2024 | marketbeat.comGalectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business UpdateAugust 13, 2024 | globenewswire.comGalectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical OfficerAugust 1, 2024 | globenewswire.comGalectin Therapeutics Inc.'s (NASDAQ:GALT) largest shareholders are retail investors with 57% ownership, insiders own 20%July 30, 2024 | finance.yahoo.comGalectin Therapeutics Inc. (NASDAQ:GALT) Sees Significant Increase in Short InterestGalectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) saw a large increase in short interest in July. As of July 15th, there was short interest totalling 4,570,000 shares, an increase of 14.0% from the June 30th total of 4,010,000 shares. Based on an average daily volume of 190,800 shares, the short-interest ratio is presently 24.0 days. Currently, 10.7% of the company's stock are sold short.July 29, 2024 | marketbeat.comGalectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200 Day Moving Average of $2.48Galectin Therapeutics (NASDAQ:GALT) Share Price Passes Above Two Hundred Day Moving Average of $2.48July 26, 2024 | marketbeat.comStockNews.com Lowers Galectin Therapeutics (NASDAQ:GALT) to SellStockNews.com downgraded shares of Galectin Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday.July 18, 2024 | marketbeat.comGalectin Therapeutics (NASDAQ:GALT) Stock Crosses Above Two Hundred Day Moving Average of $2.36Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200 Day Moving Average of $2.36June 18, 2024 | marketbeat.comGalectin Therapeutics (NASDAQ:GALT) Shares Pass Above Two Hundred Day Moving Average of $2.33Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above Two Hundred Day Moving Average of $2.33June 8, 2024 | marketbeat.comGalectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 CongressJune 4, 2024 | globenewswire.comShort Interest in Galectin Therapeutics Inc. (NASDAQ:GALT) Rises By 19.6%Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) was the recipient of a significant growth in short interest in May. As of May 15th, there was short interest totalling 3,730,000 shares, a growth of 19.6% from the April 30th total of 3,120,000 shares. Approximately 8.8% of the shares of the stock are sold short. Based on an average daily volume of 182,900 shares, the days-to-cover ratio is currently 20.4 days.May 31, 2024 | marketbeat.comGalectin Therapeutics (NASDAQ:GALT) Cut to Sell at StockNews.comStockNews.com cut shares of Galectin Therapeutics from a "hold" rating to a "sell" rating in a research note on Wednesday.May 29, 2024 | marketbeat.comGalectin Therapeutics GAAP EPS of -$0.19May 18, 2024 | seekingalpha.comGALT Stock Earnings: Galectin Therapeutics Misses EPS for Q1 2024May 15, 2024 | investorplace.comGalectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business UpdateMay 15, 2024 | globenewswire.comGalectin Therapeutics to Participate in the H.C. Wainwright BioConnect ConferenceMay 13, 2024 | finance.yahoo.comGalectin Therapeutics IncApril 30, 2024 | money.usnews.comInsider Selling: Galectin Therapeutics Inc. (NASDAQ:GALT) Major Shareholder Sells 21,323 Shares of StockApril 26, 2024 | insidertrades.comGalectin Therapeutics Inc. (NASDAQ:GALT) Major Shareholder Sells $65,248.38 in StockGalectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) major shareholder James C. Czirr sold 21,323 shares of the stock in a transaction dated Monday, April 22nd. The stock was sold at an average price of $3.06, for a total transaction of $65,248.38. Following the transaction, the insider now owns 5,925,884 shares of the company's stock, valued at approximately $18,133,205.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.April 25, 2024 | marketbeat.comGalectin Therapeutics Inc GALTApril 20, 2024 | morningstar.comShort Interest in Galectin Therapeutics Inc. (NASDAQ:GALT) Rises By 5.1%Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totalling 2,250,000 shares, an increase of 5.1% from the March 15th total of 2,140,000 shares. Approximately 5.3% of the company's stock are short sold. Based on an average trading volume of 105,800 shares, the short-interest ratio is currently 21.3 days.April 16, 2024 | marketbeat.comTraders Purchase Large Volume of Galectin Therapeutics Call Options (NASDAQ:GALT)Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) was the recipient of some unusual options trading on Thursday. Stock traders bought 10,013 call options on the company. This represents an increase of 10,784% compared to the typical daily volume of 92 call options.April 11, 2024 | marketbeat.comGalectin Therapeutics Gets DSMB's Nod To Continue Phase 2b/3 NAVIGATE Study Of BelapectinApril 9, 2024 | markets.businessinsider.comGalectin Therapeutics (NASDAQ:GALT) Earns "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $11.00 price target on shares of Galectin Therapeutics in a research report on Tuesday.April 9, 2024 | marketbeat.comGalectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitisApril 9, 2024 | finance.yahoo.com Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] GALT Media Mentions By Week GALT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GALT News Sentiment▼0.040.46▲Average Medical News Sentiment GALT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GALT Articles This Week▼151▲GALT Articles Average Week Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LUMO News CRMD News TRDA News ABUS News DNTH News TECX News PHAT News EXAI News ORIC News ANAB News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GALT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GALT Stock Alerts